Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Roflumilast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B known ✓ | Q07343 | 20/20 | 1.00 |
| ▸ | PDE4D known ✓ | Q08499 | 18/20 | 1.00 |
| ▸ | PDE4A known ✓ | P27815 | 8/20 | 1.00 |
| ▸ | PDE4C known ✓ | Q08493 | 8/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Roflumilast SCHEMBL18095182 | 1.00 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL29349467 | 1.00 | PDE4B (1.00) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL29033058 | 0.99 | PDE4B (0.98) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL29039838 | 0.99 | PDE4B (0.98) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL28150332 | 0.99 | PDE4B (0.98) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL20677818 | 0.98 | PDE4B (0.96) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| Roflumilast SCHEMBL29191360 | 0.98 | PDE4B (0.96) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL2885525 | 0.96 | PDE4B (0.93) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL30084825 | 0.96 | PDE4B (0.93) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL2887750 | 0.96 | PDE4B (0.92) | PDE4BPDE4DPDE4APDE4CABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 22006 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| EP-4743098-A1 | THERAPEUTIC USE OF FIBROBLASTS FOR THE TREATMENT OF PSORIASIS | FibroBiologics, Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| WO-2026102437-A1 | METHODS OF TREATING FRAGILE X SYNDROME USING PDE4 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260130897-A1 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | claimed |
| CN-117229211-B | NO donor type roflumilast derivative, preparation method, composition and application | 武汉科技大学 | 2026-05-12 | — | — | CN | claimed |
| US-20260128175-A1 | Methods and Systems for Analysis of Gene Expression Data | AMPEL BIOSOLUTIONS LLC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4120958-B1 | IMPLANTABLE CELL CHAMBER DEVICE AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2026-04-29 | — | — | EP | claimed |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | claimed |
| US-20260083712-A1 | METHODS FOR TREATING PATIENTS WITH OCULAR COMORBIDITIES OF AN AUTOIMMUNE DISORDER | IOLYX THERAPEUTICS, INC. (US) | 2026-03-26 | — | — | US | claimed |
| WO-2001013953-A2 | SYNERGISTIC COMBINATION OF PDE INHIBITORS AND BETA 2 ADRENOCEPTOR AGONIST | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-03-01 | — | — | WO | claimed |
| US-6174878-B1 | OR INTRANASAL COMPOSITION E.G., ASIMADOLINE (EMD-61753), ENADOLINE, BENZENEACETAMIDE, AS AN ANALGESIC FOR EAR INFECTION, SWIMMER'S EAR, ETC.; ACTIVATION OF SPECIFIC RECEPTORS SO NO SIDE EFFECTS | ALCON LABORATORIES, INC. | 2001-01-16 | — | — | US | claimed |
| US-6172060-B1 | THERAPY FOR SEXUAL DISORDERS | NITROMED, INC. | 2001-01-09 | — | — | US | claimed |
| WO-2000066123-A1 | SYNERGISTIC COMBINATION COMPRISING ROFLUMILAST AND A PDE-3 INHIBITOR | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-11-09 | — | — | WO | claimed |
| WO-2000053182-A2 | 3-CYCLOPROPYLMETHOXY-4-DIFLUOROMETHOXY-N-(3,5-DICHLOROPYRID-4-YL)BENZAMIDE IN THE TREATMENT OF MULTIPLE SCLEROSIS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-09-14 | — | — | WO | claimed |
| WO-2000050011-A1 | CONTROLLED RELEASE FORMULATION FOR TREATING COPD | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-31 | — | — | WO | claimed |
| WO-2000012076-A9 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2000-08-17 | — | — | WO | claimed |
| WO-2000012076-A1 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-03-09 | — | — | WO | claimed |
| EP-0977577-A1 | COMPOSITIONS FOR THE TREATMENT OF ARDS OR IRDS CONTAINING 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-4-PYRIDINYL)-4-(DIFLUOROMETHOXY)BENZAMIDE AND LUNG SURFACTANT | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2000-02-09 | — | — | EP | claimed |
| WO-1998035683-A1 | COMPOSITIONS FOR THE TREATMENT OF ARDS OR IRDS CONTAINING 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-4-PYRIDINYL)-4-(DIFLUOROMETHOXY)BENZAMIDE AND LUNG SURFACTANT | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-08-20 | — | — | WO | claimed |